

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 332 755 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:

06.08.2003 Bulletin 2003/32

(51) Int Cl.7: **A61K 9/127, A61K 31/335**

(21) Application number: **01919099.0**

(86) International application number:

PCT/CN01/00309

(22) Date of filing: **28.02.2001**

(87) International publication number:

WO 02/032399 (25.04.2002 Gazette 2002/17)

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU

MC NL PT SE TR

Designated Extension States:

AL LT LV MK RO SI

• **ZHOU, Wei**

Nanjing 210009 (CN)

• **CHENG, Guang**

JiangSu 210061 (CN)

• **CHENG, Peiyuan**

JiangSu 210061 (CN)

(30) Priority: **19.10.2000 CN 00119039**

(71) Applicant: **Nanjing Zhenzhong Bioengineering Company Ltd.**

JiangSu 210061 (CN)

(74) Representative: **Flaccus, Rolf-Dieter, Dr. et al**

Patentanwalt

Bussardweg 10

50389 Wesseling (DE)

(72) Inventors:

• **WENG, Guoying**

JiangSu 210061 (CN)

(54) **TAXOL LIPOSOME COMPOSITION FOR TREATMENT OF CANCER AND PREPARATION THEREOF**

(57) The present invention relates to a paclitaxel-based liposome composition for treatment of cancer, which consists substantially of the following materials by weight: paclitaxel 2-5 parts, phosphatide 20-200 parts, cholesterol 2-30 parts, amino acids 0.3-4 parts, and lyophilized excipient 10-75 parts. The products according to the present invention do not contain polyox-

ethylated castor oil, and substituted the toxic and expensive adjuvant with nontoxic media and easily obtained adjuvant, and can be actualized in industry. They have the advantages of low toxicity, good tolerance for patient, good water solubility and better stability.

EP 1 332 755 A1

Description**BACKGROUND OF THE INVENTION****5 Field of the Invention**

[0001] The present invention relates to a pharmaceutical composition for treatment of cancer, especially relates to a paclitaxel liposome composition for treatment of cancer and method of preparation thereof.

10 Description of the Related Art

[0002] Paclitaxel is an anticarcinogen found by the National Cancer Institute, USA through screening thousands of plants in the 1960s. It is generally used for treatment of oophoroma, breast carcinoma and non-small-cell lung carcinoma. Because paclitaxel is difficult to be dissolved in water and many officinal solvents, all of the paclitaxel injections provided presently in the domestic and overseas market were prepared with the complex dissolvent of polyoxyethylated castor oil and anhydrous ethanol. The polyoxyethylated castor oil in the complex dissolvent will result in the release of histamine when degraded in body, and thus may cause serious hyperallergic reaction/pleoergy.

[0003] A paclitaxel injection (trade name is Taxol) is registered in China by Bristol-Myers Squibb Company, USA, and it was pointed out in the specification that "all patients who receive the Taxol should be given in advance corticosteroid (such as dexamethasone), diphenhydramine and H₂ receptor antagonist (such as cimetidine, ranitidine) in order to prevent the occurrence of serious hyperallergic reaction." And it also said that "precipitation (crystal) may appear when diluted with physiological saline or 5% glucose before injection. So it is necessary to be filtrated with 0.22 μm millipore filter to assure the safety in administration." Also paclitaxel itself has haematics toxicity, bone marrow depression, leukopenia, thrombocytopenia, anemia and other toxicities. Therefore, change of paclitaxel's dosage form are demanded urgently to increase its solubility, improve its stability and clinical compliance, and avoid the allergic reaction caused by the above complex dissolvent and other toxic side effect.

[0004] Practicable progress was achieved from the basic researches of paclitaxel liposome in the early 1990s and the recent preclinical study. The experiments indicated that the paclitaxel liposome preparation had similar therapeutic effectiveness with reduced toxicity and improved tolerance compared to the paclitaxel injection preparation. SharmaA reported a paclitaxel liposome (code name TTL) made from three synthetic phosphatides (Int. J. Cancer 1997, 71, 103-107) with better stability than the paclitaxel liposome (code name ETL) made from single lecithin. But it did not say how much the difference of stability was between the two preparations, and only mentioned that the ETL preparation maintained its stability for 24 hours after dissolved in water and that the solvent used was benzene or butanol. Benzene has much toxicity when used as solvent.

[0005] In US patent No. 5,415,869 (1995), it was mentioned that aggregation occurred in the paclitaxel liposome preparation made from single lecithin. Thus electronegative or electropositive ingredient such as phosphatidyl glycerol (PG) was introduced. The ratio of lecithin to PG adopted by the patent was 9:1 or 3:7 while chloroform was used as solvent, the paclitaxel liposome did not aggregation. But when the ratio was 5:5 the paclitaxel liposome crystal precipitated. PG is difficult to obtain due to its low content in lecithin. And there are only expensive products of PG of reagent grade overseas. Also chloroform has too much toxicity when used as solvent.

SUMMARY OF THE PRESENT INVENTION

[0006] One object of the present invention is to provide a paclitaxel liposome composition for treatment of cancer without polyoxyethylated castor oil.

[0007] The second object of the present invention is to provide a paclitaxel liposome composition for treatment of cancer, which has good colliuefaction with the water soluble transfusion and can be infused directly into 5% glucose solution for intravenous drip after shaking, and has reduced toxicity and can avoid the hyperallergic reaction caused by the complex dissolvent and has improved stability and relatively lower cost.

[0008] The third object of the present invention is to provide a method of preparation of paclitaxel liposome composition for treatment of cancer without polyoxyethylated castor oil.

[0009] The fourth object of the present invention is to provide a method of preparation of paclitaxel liposome composition for treatment of cancer with improved water solubility and stability using liposome imbedding technique.

[0010] These and other objects will be further described and represented through the following detailed illustration.

DETAILED DESCRIPTION OF THE INVENTION

[0011] In the present invention, the paclitaxel liposome composition for treatment of cancer consists substantially of

the following materials by weight:

Paclitaxel 2-5 parts, Phosphatide 20-200 parts, Cholesterol 2-30 parts, Amino acids 0.3-4 parts, Lyophilized excipient 10-75 parts.

[0012] Furthermore, the paclitaxel liposome composition for treatment of cancer of the present invention consists substantially of the following materials by weight:

Paclitaxel 3-5 parts, Phosphatide 40-160 parts, Cholesterol 5-25 parts, Amino acids 0.8-3 parts, Lyophilized excipient 20-65 parts.

[0013] The paclitaxel liposome composition for treatment of cancer of the present invention may also consist substantially of the following materials by weight:

Paclitaxel 3-5 parts, Phosphatide 60-120 parts, Cholesterol 8-20 parts, Amino acids 1.0-2 parts, Lyophilized excipient 30-60 parts.

[0014] The paclitaxel liposome composition for treatment of cancer of the present invention does not contain polyoxyethylated castor oil.

[0015] Furthermore, in the paclitaxel liposome composition for treatment of cancer of the present invention, the said lyophilized excipient is mannitol, sucrose, glucose, or lactose which can be solid suited for injection. The said amino acid can be lysine, threonine or methionine. The said phosphatide is egg yolk lecithin or soy bean lecithin for injection.

[0016] If necessary, the composition of the present invention can also be added or together with other anti-tumor drugs. The suitable anti-tumor drug and adjuvant may be diphenhydramine, cimitidine, niacinamide, VB₆, VB₁, or may also be bear gall powder, rhodiola root, ginseng, American ginseng, cordyceps, ganoderma lucidum and hsueh-lien-hua, etc.

[0017] The paclitaxel liposome composition for treatment of cancer of the present invention can be prepared by the following method, and includes substantially the following materials by weight:

Paclitaxel 2-5 parts, Phosphatide 20-200 parts, Cholesterol 2-30 parts, Amino acids 0.3-4 parts, Lyophilized excipient 10-75 parts.

[0018] Paclitaxel, phosphatide, cholesterol are agitated and dissolved successively in isopropanol or ethanol using the above ratios to obtain a clear solution. Then the solution is placed in a constant temperature water bath with a temperature of 50-60°C. After the solvent is removed with a rotatory evaporator under reduced pressure, a membrane is formed therefrom. The aqueous solution of amino acids and lyophilized excipient dissolved in the above ratios is introduced. And then hydration, sonication or homogenization is conducted to attain the liposome size above 0.1 μm, preferably 0.2-5 μm. After sterilization filtration, the gain is subpackaged into containers such as ampoules or vials etc., and lyophilized to obtain white lumpy paclitaxel liposome. Nitrogen, helium or argon gas can be aerated when sealing or capping.

[0019] Furthermore, the paclitaxel liposome composition for treatment of cancer of the present invention can be prepared by the following method, and includes substantially the following materials by weight:

Paclitaxel 3-5 parts, Phosphatide 40-160 parts, Cholesterol 5-25 parts, Amino acids 0.8-3 parts, Lyophilized excipient 20-65 parts.

[0020] Paclitaxel, phosphatide, cholesterol are agitated and dissolved successively in isopropanol or ethanol using the above ratios to obtain a clear solution. Then the solution is placed in a constant temperature water bath with a temperature of 50-60°C. After the solvent is removed with a rotatory evaporator under reduced pressure, a membrane is formed therefrom. The aqueous solution of amino acids and lyophilized excipient dissolved in the above ratios is introduced. And then hydration, sonication or homogenization is conducted to attain the liposome size 0.1-5 μm. After sterilization filtration, the gain is subpackaged into containers such as ampoules or vials etc., and lyophilized to obtain white lumpy paclitaxel liposome. Nitrogen, helium or argon gas can be aerated when sealing or capping.

[0021] The paclitaxel liposome composition for treatment of cancer of the present invention can also be prepared by the following method, and includes substantially the following materials by weight:

Paclitaxel 3-5 parts, Phosphatide 60-120 parts, Cholesterol 8-20 parts, Amino acids 1.0-2 parts, Lyophilized excipient 30-60 parts.

[0022] Paclitaxel, phosphatide, cholesterol are agitated and dissolved successively in isopropanol or ethanol in the above ratios to obtain a clear solution. Then the solution is placed in a constant temperature water bath with a temperature of 50-60°C. After the solvent is removed with a rotatory evaporator under reduced pressure, a membrane is formed therefrom. The aqueous solution of amino acids and lyophilized excipient dissolved in the above ratios is introduced. And then hydration, sonication or homogenization is conducted to attain the liposome size above 0.1 μm. After sterilization filtration, the gain is subpackaged into containers such as ampoules or vials etc., and lyophilized to obtain white lumpy paclitaxel liposome. Nitrogen, helium or argon gas can be aerated when sealing or capping.

[0023] In the above method, the said lyophilized excipient is mannitol, sucrose, glucose, or lactose. The said amino acid can be lysine, threonine or methionine. The said phosphatide is egg yolk lecithin or soy bean lecithin for injection.

[0024] The products of the present invention do not contain polyoxyethylated castor oil and substitute the toxic dissolvent and expensive adjuvant with nontoxic dissolvent and easily obtained adjuvant, and can be executed in industry

scale. So they have advantages of low toxicity, good water solubility and better stability, etc. They can be infused directly into 5% glucose solution for intravenous drip after shaking and avoid the hyperallergic reaction caused by the complex dissolvent, and have relatively lower cost.

[0025] The paclitaxel liposome preparation prepared according to the present invention has similar anti-cancer effectiveness to the commercial paclitaxel injection, as shown in table 1.

Table 1.

The inhibitory effect of paclitaxel liposome for injection and commercial paclitaxel injection on S-180					
Group	Group	Dosage (mg/kg)	Number of animals		Inhibition ratio (%)
			Before administration	After administration	
	Paclitaxel liposome	20.0	10	10	0.826±0.204**
	Paclitaxel liposome	14.0	10	10	0.896±0.293**
	Paclitaxel liposome	9.8	10	10	1.114±0.425
	Paclitaxel injection	14.0	10	10	0.860±0.177**
	Paclitaxel injection	9.8	10	9	1.180±0.299
	Control		10	10	1.612±0.705

** P<0.01, compared with the control group.

[0026] In the present invention, the single lecithin together with cholesterol and amino acids is used as the stabilizing agent. Amino acids are amphoteric material, which can show electrification at given pHs such as in the present technical scheme. So this will prevent aggregation and precipitations of taxol crystal. The method uses easily obtained material so that the cost is low compared to the reported methods, in which electronegative ingredient such as PG or electro-positive ingredient were added. And the obtained paclitaxel liposome has better stability than that only with single lecithin. Aggregation does not occur and crystal does not precipitate in the obtained paclitaxel liposome when standing after dissolved with water (table 2).

Table 2.

Data of paclitaxel liposome's stability at low temperature (2-10°C)			
Lot number	Time (month)	Appearance	Microscopic examination (1 × 1600)
No. 1	0	Loose offwhite lump	No crystal after dissolved, no aggregation
	1	Loose offwhite lump	No crystal after dissolved, no aggregation
	6	Loose offwhite lump	No crystal after dissolved, no aggregation
	12	Loose offwhite lump	No crystal after dissolved, no aggregation
No. 2	0	Loose offwhite lump	No crystal after dissolved, no aggregation
	1	Loose offwhite lump	No crystal after dissolved, no aggregation
	6	Loose offwhite lump	No crystal after dissolved, no aggregation
	12	Loose offwhite lump	No crystal after dissolved, no aggregation

[0027] The paclitaxel liposome preparation according to the present invention has better colliuefaction with the glucose for injection and physiological saline. The content of paclitaxel in the obtained preparation is 4-6 mg/ml, which is a suitable concentration for clinical administration and can be used in clinical therapy with the same amount as the commercial paclitaxel injection. According to body surface area, the dosage is 175 mg/m² intravenous drip.

[0028] In the present invention, all materials and adjuvants can be purchased in the market.

[0029] The present invention will be illustrated further with several examples. But these examples are used for illus-

tration of the present invention, and do not limit the scope of the present invention.

[0030] If not being pointed out specially, all parts or measurements are weight units based on the total weight.

Example 1

[0031] In aseptic condition, paclitaxel for injection (2.5g), refined egg yolk lecithin for injection (30g) and cholesterol (2.7g) were introduced into a round-bottomed flask. And proper amount of isopropanol (about 300ml) was added to make the mixture dissolved completely as clear solution. Then underpressure drying was conducted with a rotary evaporator in a constant temperature water bath (50°C) to form a membrane. 5% mannitol solution containing 2.8g lysine was added to dissolve the membrane, and a sonifier was used for ultrasonic pulverization. After being filtrated with 0.22 μ m filter membrane to degerm, the solution was subpackaged into ampoules (or vials) so that 25mg paclitaxel was contained in each bottle. Lyophilization was conducted followed by sealing in inert gases to obtain white lumpy paclitaxel liposome preparation.

Example 2

[0032] In aseptic condition, paclitaxel for injection (5.0g), refined soy bean lecithin for injection (72g) and cholesterol (6g) were introduced into a round-bottomed flask. And proper amount of ethanol (about 800ml) was added to make the mixture dissolved completely as clear solution. Then underpressure drying was conducted with a rotary evaporator in a constant temperature water bath (50°C) to form a membrane. 5% mannitol solution containing 3.4g lysine was added to dissolve the membrane, and a high-pressure refiner was used for homogenization. After being filtrated with 0.22 μ m filter membrane to degerm, the solution was subpackaged into ampoules (or vials) so that 30mg paclitaxel was contained in each bottle. Lyophilization was conducted followed by sealing in inert gases to obtain white lumpy paclitaxel liposome preparation.

Example 3

[0033] In aseptic condition, paclitaxel for injection (2.5g), refined soy bean lecithin for injection (30g) and cholesterol (2.7g) were introduced into a round-bottomed flask. And proper amount of isopropanol (about 400ml) was added to make the mixture dissolved completely as clear solution. Then underpressure drying was conducted with a rotary evaporator in a constant temperature water bath (50°C) to form a membrane. 7.5% sucrose solution containing 2.0g methionine was added to dissolve the membrane, and a sonifier was used for ultrasonic pulverization. After being filtrated with 0.22 μ m filter membrane to degerm, the solution was subpackaged into ampoules (or vials) so that 20mg paclitaxel was contained in each bottle. Lyophilization was conducted followed by sealing in inert gases to obtain white lumpy paclitaxel liposome preparation.

Example 4

[0034] In aseptic condition, paclitaxel for injection (5.0g), refined egg yolk lecithin for injection (72g) and cholesterol (6g) were introduced into a round-bottomed flask. And proper amount of ethanol (about 1500ml) was added to make the mixture dissolved completely as clear solution. Then underpressure drying was conducted with a rotary evaporator in a constant temperature water bath (50°C) to form a membrane. 7.5% mannitol solution containing 3.5g threonine was added to dissolve the membrane, and a high-pressure refiner was used for homogenization. After being filtrated with 0.22 μ m filter membrane to degerm, the solution was subpackaged into ampoules (or vials) so that 30mg paclitaxel was contained in each bottle. Lyophilization was conducted followed by sealing in inert gases to obtain white lumpy paclitaxel liposome preparation.

Example 5

[0035] In aseptic condition, paclitaxel for injection (5.0g), refined egg yolk lecithin for injection (65g) and cholesterol (6.5g) were introduced into a round-bottomed flask. And proper amount of ethanol (about 1500ml) was added to make the mixture dissolved completely as clear solution. Then underpressure drying was conducted with a rotary evaporator in a constant temperature water bath (50°C) to form a membrane. 7.5% lactose solution containing 3.8g lysine was added to dissolve the membrane, and a high-pressure refiner was used for homogenization. After being filtrated with 0.22 μ m filter membrane to degerm, the solution was subpackaged into ampoules (or vials) so that 20mg paclitaxel was contained in each bottle. Lyophilization was conducted followed by sealing in inert gases to obtain white lumpy paclitaxel liposome preparation.

Example 6

[0036] In aseptic condition, paclitaxel for injection (2.0g), refined egg yolk lecithin for injection (42g) and cholesterol (4g) were introduced into a round-bottomed flask. And proper amount of ethanol (about 260ml) was added to make the mixture dissolved completely as clear solution. Then underpressure drying was conducted with a rotary evaporator in a constant temperature water bath (60°C) to form a membrane. 5% mannitol solution (about 400ml) containing 2.0g lysine was added to dissolve the membrane, and a high-pressure refiner was used for homogenization. After being filtrated with 0.22 μ m filter membrane to degerm, the solution was subpackaged into ampoules (or vials). Lyophilization was conducted followed by sealing in inert gases to obtain white lumpy paclitaxel liposome preparation.

Example 7

[0037] In aseptic condition, paclitaxel for injection (2.8g), refined egg yolk lecithin for injection (60g) and cholesterol (4g) were introduced into a round-bottomed flask. And proper amount of ethanol (about 350ml) was added to make the mixture dissolved completely as clear solution. Then underpressure drying was conducted with a rotary evaporator in a constant temperature water bath (55°C) to form a membrane. 5% mannitol solution (about 300ml) containing 2.4g threonine was added to dissolve the membrane, and a high-pressure refiner was used for homogenization. After being filtrated with 0.22 μ m filter membrane to degerm, the solution was subpackaged into ampoules (or vials). Lyophilization was conducted followed by sealing in inert gases to obtain white lumpy paclitaxel liposome preparation.

Example 8

[0038] In aseptic condition, paclitaxel for injection (3.5g), refined soy bean lecithin for injection (100g) and cholesterol (4.5g) were introduced into a round-bottomed flask. And proper amount of isopropanol (about 1000ml) was added to make the mixture dissolved completely as clear solution. Then underpressure drying was conducted with a rotary evaporator in a constant temperature water bath (58°C) to form a membrane. 5% sucrose solution (about 500ml) containing 3.1g methionine was added to dissolve the membrane, and a high-pressure refiner was used for homogenization. After being filtrated with 0.22 μ m filter membrane to degerm, the solution was subpackaged into ampoules (or vials). Lyophilization was conducted followed by sealing in inert gases to obtain white lumpy paclitaxel liposome preparation.

Example 9

[0039] In aseptic condition, paclitaxel for injection (4.5g), refined soy bean lecithin for injection (122g) and cholesterol (8g) were introduced into a round-bottomed flask. And proper amount of isopropanol (about 1200ml) was added to make the mixture dissolved completely as clear solution. Then underpressure drying was conducted with a rotary evaporator in a constant temperature water bath (52°C) to form a membrane. 5% mannitol solution (about 1000ml) containing 3.1g threonine was added to dissolve the membrane, and a high-pressure refiner was used for homogenization. After being filtrated with 0.22 μ m filter membrane to degerm, the solution was subpackaged into ampoules (or vials). Lyophilization was conducted followed by sealing in inert gases to obtain white lumpy paclitaxel liposome preparation.

Example 10

[0040] In aseptic condition, paclitaxel for injection (5.0g), refined egg yolk lecithin for injection (100g) and cholesterol (15g) were introduced into a round-bottomed flask. And proper amount of ethanol (about 1200ml) was added to make the mixture dissolved completely as clear solution. Then underpressure drying was conducted with a rotary evaporator in a constant temperature water bath (53°C) to form a membrane. 5% mannitol solution (about 1000ml) containing 3.8g lysine was added to dissolve the membrane, and a high-pressure refiner was used for homogenization. After being filtrated with 0.22 μ m filter membrane to degerm, the solution was subpackaged into ampoules (or vials). Lyophilization was conducted followed by sealing in inert gases to obtain white lumpy paclitaxel liposome preparation.

Example 11

[0041] In aseptic condition, paclitaxel for injection (5.0g), refined egg yolk lecithin for injection (120g) and cholesterol (21g) were introduced into a round-bottomed flask. And proper amount of ethanol (about 1500ml) was added to make the mixture dissolved completely as clear solution. Then underpressure drying was conducted with a rotary evaporator in a constant temperature water bath (59°C) to form a membrane. 5% glucose solution (about 1400ml) containing 2.4g

threonine was added to dissolve the membrane, and a high-pressure refiner was used for homogenization. After being filtrated with 0.22 μ m filter membrane to degerm, the solution was subpackaged into ampoules (or vials) so that 30mg paclitaxel was contained in each bottle. Lyophilization was conducted followed by sealing in inert gases to obtain white lumpy paclitaxel liposome preparation.

Example 12

[0042] In aseptic condition, paclitaxel for injection (4.0g), refined egg yolk lecithin for injection (120g) and cholesterol (18g) were introduced into a round-bottomed flask. And proper amount of ethanol (about 1200ml) was added to make the mixture dissolved completely as clear solution. Then underpressure drying was conducted with a rotary evaporator in a constant temperature water bath (52°C) to form a membrane. 5% lactose solution (about 1000ml) containing 3.0g methionine was added to dissolve the membrane, and a high-pressure refiner was used for homogenization. After being filtrated with 0.22 μ m filter membrane to degerm, the solution was subpackaged into ampoules (or vials) so that 25mg paclitaxel was contained in each bottle. Lyophilization was conducted followed by sealing in inert gases to obtain white lumpy paclitaxel liposome preparation.

Example 13

[0043] In aseptic condition, paclitaxel for injection (5.0g), soy bean lecithin (200g) and cholesterol (30g) were introduced into a round-bottomed flask. And proper amount of ethanol (about 2000ml) was added to make the mixture dissolved completely as clear solution. Then underpressure drying was conducted with a rotary evaporator in a constant temperature water bath (57°C) to form a membrane. 5% glucose solution (about 1400ml) containing 4.0g lysine was added to dissolve the membrane, and a high-pressure refiner was used for homogenization. After being filtrated with 0.22 μ m filter membrane to degerm, the solution was subpackaged into ampoules (or vials) so that 20mg paclitaxel was contained in each bottle. Lyophilization was conducted followed by sealing in inert gases to obtain white lumpy paclitaxel liposome preparation.

Example 14

[0044] In aseptic condition, paclitaxel for injection (3.0g), refined egg yolk lecithin for injection (80g) and cholesterol (5.0g) were introduced into a round-bottomed flask. And proper amount of isopropanol (about 700ml) was added to make the mixture dissolved completely as clear solution. Then underpressure drying was conducted with a rotary evaporator in a constant temperature water bath (55°C) to form a membrane. 5% mannitol solution (about 1000ml) containing 2.4g lysine was added to dissolve the membrane, and a high-pressure refiner was used for homogenization. After being filtrated with 0.22 μ m filter membrane to degerm, the solution was subpackaged into ampoules (or vials) so that 15mg paclitaxel was contained in each bottle. Lyophilization was conducted followed by sealing in inert gases to obtain white lumpy paclitaxel liposome preparation.

Claims

1. A paclitaxel liposome composition for treatment of cancer, wherein the composition consists substantially of the following materials by weight:
Paclitaxel 2-5 parts, Thosphatide 20-200 parts, Cholesterol 2-30 parts, Amino acids 0.3-4 parts, Lyophilized excipient 10-75 parts.
2. The paclitaxel liposome composition for treatment of cancer according to Claim 1, wherein the composition consists substantially of the following materials by weight:
Paclitaxel 3-5 parts, Phosphatide 40-160 parts, Cholesterol 5-25 parts, Amino acids 0.8-3 parts, Lyophilized excipient 20-65 parts.
3. The paclitaxel liposome composition for treatment of cancer according to Claim 1, wherein the composition consists substantially of the following materials by weight:
Paclitaxel 3-5 parts, Phosphatide 60-120 parts, Cholesterol 8-20 parts, Amino acids 1.0-2 parts, Lyophilized excipient 30-60 parts.
4. The paclitaxel liposome composition for treatment of cancer according to Claims 1 to 3, wherein the composition does not contain polyoxyethylated castor oil.

5. The paclitaxel liposome composition for treatment of cancer according to Claims 1 to 4, wherein the said lyophilized excipient is mannitol, sucrose, glucose, or lactose.
6. The paclitaxel liposome composition for treatment of cancer according to Claims 1 to 4, wherein the said amino acid can be lysine, threonine or methionine.
7. The paclitaxel liposome composition for treatment of cancer according to Claims 1 to 4, wherein the said phosphatide is egg yolk lecithin or soy bean lecithin for injection.
8. A method of preparing the paclitaxel liposome composition for treatment of cancer according to Claims 1 to 4, wherein the composition consists substantially of the following materials by weight:
Paclitaxel 2-5 parts, Phosphatide 20-200 parts, Cholesterol 2-30 parts, Amino acids 0.3-4 parts, Lyophilized excipient 10-75 parts.
Paclitaxel, phosphatide, cholesterol are agitated and dissolved successively in isopropanol or ethanol in the above ratios to obtain a clear solution. Then the solution is placed in a constant temperature water bath with a temperature of 50-60°C. After the solvent is removed with a rotatory evaporator under reduced pressure, a membrane is formed therefrom. The aqueous solution of amino acids and lyophilized excipient dissolved in the above ratios is introduced. And then hydration, sonication or homogenization is conducted to attain the liposome size above 0.1 µm. After sterilization filtration, the gain is subpackaged into containers, and nitrogen, helium or argon gas is aerated after being lyophilized to obtain paclitaxel liposome preparation.
9. The method for preparing the paclitaxel liposome composition for treatment of cancer according to Claims 1 to 4, wherein the composition consists substantially of the following materials by weight:
Paclitaxel 3-5 parts, Phosphatide 40-160 parts, Cholesterol 5-25 parts, Amino acids 0.8-3 parts, Lyophilized excipient 20-65 parts.
Paclitaxel, phosphatide, cholesterol are agitated and dissolved successively in isopropanol or ethanol in the above ratios to obtain a clear solution. Then the solution is placed in a constant temperature water bath with a temperature of 50-60°C. After the solvent is removed with a rotatory evaporator under reduced pressure, a membrane is formed therefrom. The aqueous solution of amino acids and lyophilized excipient dissolved in the above ratios is introduced. And then hydration, sonication or homogenization is conducted. After sterilization filtration, the gain is subpackaged into containers, and nitrogen, helium or argon gas is aerated after being lyophilized to obtain paclitaxel liposome preparation.
10. The method for preparing the paclitaxel liposome composition for treatment of cancer according to Claims 1 to 4, wherein the composition consists substantially of the following materials by weight:
Paclitaxel 3-5 parts, Phosphatide 60-120 parts, Cholesterol 8-20 parts, Amino acids 1.0-2 parts, Lyophilized excipient 30-60 parts.
Paclitaxel, phosphatide, cholesterol are agitated and dissolved successively in isopropanol or ethanol in the above ratios to obtain a clear solution. Then the solution is placed in a constant temperature water bath with a temperature of 50-60°C. After the solvent is removed with a rotatory evaporator under reduced pressure, a membrane is formed therefrom. The aqueous solution of amino acids and lyophilized excipient dissolved in the above ratios is introduced. And then hydration, sonication or homogenization is conducted. After sterilization filtration, the gain is subpackaged into containers, and nitrogen, helium or argon gas is aerated after being lyophilized to obtain paclitaxel liposome preparation.
11. The method for preparing a paclitaxel liposome composition for treatment of cancer according to Claims 8 to 10, wherein the said lyophilized excipient is mannitol, sucrose, glucose, or lactose.
12. The method for preparing a paclitaxel liposome composition for treatment of cancer according to Claims 8 to 10, wherein the said amino acid can be lysine, threonine or methionine.
13. The method for preparing a paclitaxel liposome composition for treatment of cancer according to Claims 8 to 10, wherein the said phosphatide is egg yolk lecithin or soy bean lecithin for injection.

INTERNATIONAL SEARCH REPORT

 International application No.
PCT/CN01/00309

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K 9/127 A61K 31/335 ✓ According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched CHINA NON-PATENT DOCUMENT Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CA, CHINA PHARMACEUTICAL ABSTRACT		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,648,090(Aquilur Rahman, Gaithersburg, Md)15.07 1997 SEE: Examples and Claims	1-13
A	WO 94/26254(THE LIPOSOME COMPANY, INC.)24.11.94 SEE: Examples and Claims	1-13
A	US 6,090,955(REGINE RESZKA, SCHWANEBECK et.al.)18.07.2000 SEE: Claims	
A	PHARMACEUTICAL BIOTECHNOLOGY 1996, 3(3): pp. 154-157, Jialin Yan. et. al. "Preparation of Taxol liposome and their study in suppressing tumor"see whole document	1-13
A	CN 1148957 07.05.97 Hairu Zhang, et. al. SEE: Claims	1-13
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim (S) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family	
Date of the actual completion of the international search 20.Jul.2001(20.07.01)		Date of mailing of the international search report 02 AUG 2001 (02.08.01)
Name and mailing address of the ISA/CN Nitucheng Rd., Jimen Bridge, Haidian District, 100088 Beijing, China Facsimile No. 86-10-62019451		Authorized officer Yingzi Zhou Telephone No. 86-10-62093104

Form PCT/ISA/210(first sheet)(July 1998)

INTERNATIONAL SEARCH REPORT
 Information on patent family members

 International application No.
 PCT/CN01/00309

Patent document cited in search report	Publication date	Patent family members(s)	Publication date
US 5648090	15-07-97	WO 9318751	30-09-93
		AU 3922193	21-10-93
		US 5424073	13-06-95
		EP 0706373	17-04-96
		DE 69329-73	24-08-00
		ES 2148223	16-10-00
US 6090955	18-07-00	DE4430593	22-02-96
		WO 9605821	29-02-96
		EP 0776202	04-06-97
		DE 4447770	26-03-98
		DE 59508360	21-06-00
WO 9426254	24-11-94	AU 6833994	12-12-94

Form PCT/ISA /210 (patent family annex) (July 1998)